Gacos-B (01167) rose more than 18% during the intraday period. As of press release, it was up 12.29% to HK$2.65, with a turnover of HK$21.261,600.
The Zhitong Finance App learned that Gacos-B (01167) rose more than 18% during the intraday period. As of press release, it had risen 12.29% to HK$2.65, with a turnover of HK$21.2616 million.
According to the news, Gacos announced that the new drug clinical trial application (IND) for its self-developed P53 Y220C activator JAB-30300 has been approved by the US Food and Drug Administration (FDA). The company will conduct a phase i/IIa clinical trial for advanced solid tumors in the US to evaluate the safety and efficacy of JAB30300.
According to the announcement, the company also plans to submit clinical applications for new drugs to the Drug Evaluation Center of the State Drug Administration in China. After approval, clinical trials will be carried out simultaneously in China and the US. Currently, only one similar project of the P53 Y220C activator in the world is in the first clinical phase. The JAB-30300 is expected to be one of the first products to be launched.